Background The clinical impact of different prophylactic anticoagulation regimens among
hospitalized patients with coronavirus disease 2019 (COVID-19) remains unclear. We …

Background Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …

Coronavirus disease 2019 (COVID‐19) is associated with a hypercoagulable state. It has
been hypothesized that higher‐dose anticoagulation, including therapeutic‐dose and …

Abstract Introduction Coronavirus disease (COVID‐19) is associated with a high incidence
of thrombosis and mortality despite standard anticoagulant thromboprophylaxis. There is …

Background Because of the high risk of thrombotic complications (TCs) during SARS-CoV-2
infection, several scientific societies have proposed to increase the dose of preventive …

Objective We aimed to perform a meta-analysis to summarize the overall evidence from
randomized controlled trials related to higher-intensity anticoagulation in hospitalized …

Background Thromboembolic events are common complications of COVID-19. Clinical study
results on safety and efficacy of anticoagulation in COVID-19 are controversial. Material and …

We conducted a systematic review and a meta-analysis to assess the association of
anticoagulants and their dosage with in-hospital all-cause mortality in COVID-19 patients …

Hypercoagulability in coronavirus disease 2019 (COVID-19) may aggravate disease
severity during hospitalization but the reported survival benefits from anticoagulation (AC) …

Background Thrombotic complications are considered among the main extrapulmonary
manifestations of coronavirus disease 2019 (COVID-19). The optimal type and duration of …